Genetic Technologies Ltd. ADR (GENE) News

Genetic Technologies Ltd. ADR (GENE): $0.93

0.03 (+3.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter GENE News Items

GENE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GENE News Highlights

  • GENE's 30 day story count now stands at 2.
  • Over the past 13 days, the trend for GENE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • ASX are the most mentioned tickers in articles about GENE.

Latest GENE News From Around the Web

Below are the latest news stories about GENETIC TECHNOLOGIES LTD that investors may wish to consider to help them evaluate GENE as an investment opportunity.

Genetic Technologies Presented Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk at ASCOGI Cancer Symposium

MELBOURNE, Australia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce a poster presentation by Dr Erika Spaeth at the prestigious American Society of Clinical Oncology Gastroenterology Cancer Symposium in San Francisco last weekend. The Poster titled “Improvement of a clinical colorectal cancer risk prediction model integrating polyg

Yahoo | January 24, 2023

Genetic Technologies Provides Business Update

MELBOURNE, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to provide the following business update for the first half of the 2023 financial year. Operating in the multibillion dollar predictive and consumer genomics markets, GTG has achieved five consecutive quarters of growth. Our portfolio features the most comprehensi

Yahoo | January 11, 2023

GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes

MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is delighted to announce the publication of a peer-reviewed paper describing the development and validation of the polygenic risk scores that underlie the risk predictions for cardiovascular diseases and type 2 diabetes in the geneType Multi-Risk Test. The paper is coauth

Yahoo | December 6, 2022

Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease

MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies (ASX:GTG, NASDAQ:GENE), a global leader in guideline driven Genomics based tests in health, wellness and serious disease will be hosting an interview between Dr Erika Spaeth (PhD Director of Clinical & Scientific Affairs and GTG in the US) and Adjunct Professor Charles Siles Health (Executive Director and founder of Siles Health). A/Prof. Charles Siles, Obstetrician and Gynaecologist operates nine (9) clinics across Vic

Yahoo | November 10, 2022

Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer Prevention

MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is delighted to announce the publication of a validation study evaluating the performance of the geneType ovarian cancer test. This 10 year prospective cohort study utilizes data from more than 190,000 women and has been published in the prestigious European Journal of Canc

Yahoo | November 9, 2022

Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar Details

MELBOURNE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious disease has released its results for the quarter ended September 30, 2022 (Q1 FY23). Q1 FY23 Highlights: Revenue from customers of A$1.93 million for the quarter, up 375% from prior corresponding period (Q1 FY22), highlighting commercial progress with revenues anchoring from GTG’s

Yahoo | October 25, 2022

Genetic Technologies Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

RedChip Companies will air a new interview with Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) ("Company", "GTG"), a global leader in genomics-based tests in health, wellness, and serious disease, on The RedChip Money Report® on Bloomberg TV, this Saturday, October 15, at 7 p.m. Eastern Time (ET).

Yahoo | October 13, 2022

Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer

MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the recent publication of a paper in the Journal of Precision Medicine authored by GTG science team members, Dr Erika Spaeth, Director of Clinical Affairs, Dr Richard Allman, Chief Scientific Officer, and Dr Gillian Dite, Senior Biostatistician. Publication highlig

Yahoo | September 29, 2022

Genetic Technologies Provides Update on US Operations and Payer Engagement

MELBOURNE, Australia, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”, “GENE”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease, is pleased to report excellent commercial progress in the USA strategic operations with the following updates: Strategic Highlights: Active engagement with 11 US payer groups with an initial target list of 30 with coverage in tens of millions of livesEngagement wi

Yahoo | September 2, 2022

GENE Momentum building - a year in review

MELBOURNE, Australia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results for the year ended June 30, 2022. It has been an exciting 12 months focused on our commercialisation journey. We now have the most comprehensive portfolio of genetic based tests available for individuals and animals. In addition to our p

Yahoo | August 30, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7781 seconds.